Early studies showed the potential vaccine produced “robust antibody responses” greater than those seen in recovering patients.
Novavax is ready to start its Phase 3 trial of an experimental COVID-19 vaccine in the UK.
The US biotechnology firm plans to enrol up to 10,000 volunteers aged between 18 and 84 over the next four to six weeks.
The company joins AstraZeneca, Pfizer, and Moderna as its vaccine candidate enters the final step of the regulatory approvals process.
There are almost 40 potential vaccines being tested globally and more than 140 others in the early stages of testing, according to the World Health Organisation.Advertisement
Half of the volunteers in the Novavax trial will have two shots of NVX-CoV2373 with Matrix-M, the company’s adjuvant which is intended to strengthen the vaccine. Half will be given a placebo.